BRPI0512757A - método de estabilização de lipossomos catiÈnicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamìdia, malária ou tuberculose e sistema de distribuição - Google Patents

método de estabilização de lipossomos catiÈnicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamìdia, malária ou tuberculose e sistema de distribuição

Info

Publication number
BRPI0512757A
BRPI0512757A BRPI0512757-2A BRPI0512757A BRPI0512757A BR PI0512757 A BRPI0512757 A BR PI0512757A BR PI0512757 A BRPI0512757 A BR PI0512757A BR PI0512757 A BRPI0512757 A BR PI0512757A
Authority
BR
Brazil
Prior art keywords
vaccine
liposome
malaria
delivery system
chlamydia
Prior art date
Application number
BRPI0512757-2A
Other languages
English (en)
Inventor
Jesper Davidsen
Ida Rosenkrands
Peter Andersen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512757(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of BRPI0512757A publication Critical patent/BRPI0512757A/pt
Publication of BRPI0512757B1 publication Critical patent/BRPI0512757B1/pt
Publication of BRPI0512757B8 publication Critical patent/BRPI0512757B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODO DE ESTABILIZAçãO DE LIPOSSOMOS CATIÈNICOS EM FORMULAçõES AQUOSAS, PRODUTO DE LIPOSSOMO, ADJUVANTE DE VACINA, VACINA CONTRA CLAMìDIA, MALáRIA OU TUBERCULOSE E SISTEMA DE DISTRIBUIçãO A presente invenção refere-se a formulações de lipossomos que são fisicamente estáveis. Em particular, a presente invenção refere-se à estabilização estérica de lipossomos catiónicos por incorporação de glicolipídios nos lipossomos. Os lipossomos estabilizados podem ser utilizados como um adjuvante para componentes antigênicos ou como um sistema de distribuição de medicamentos. Em particular, a invenção refere-se a vacinas com adjuvantes em meios aquosos para imunização, em que o produto final é estável.
BRPI0512757A 2004-07-07 2005-07-05 método de estabilização de lipossomos catiônicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamídia, malária ou tuberculose e sistema de distribuição BRPI0512757B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200401070 2004-07-07
DKPA200401070 2004-07-07
PCT/DK2005/000467 WO2006002642A2 (en) 2004-07-07 2005-07-05 Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids

Publications (3)

Publication Number Publication Date
BRPI0512757A true BRPI0512757A (pt) 2008-04-08
BRPI0512757B1 BRPI0512757B1 (pt) 2021-04-06
BRPI0512757B8 BRPI0512757B8 (pt) 2021-05-25

Family

ID=34982425

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512757A BRPI0512757B8 (pt) 2004-07-07 2005-07-05 método de estabilização de lipossomos catiônicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamídia, malária ou tuberculose e sistema de distribuição

Country Status (16)

Country Link
EP (1) EP1765289B1 (pt)
JP (1) JP4987704B2 (pt)
KR (1) KR101275837B1 (pt)
CN (1) CN1980638B (pt)
AT (1) ATE406874T1 (pt)
AU (1) AU2005259685B2 (pt)
BR (1) BRPI0512757B8 (pt)
CA (1) CA2572985C (pt)
DE (1) DE602005009535D1 (pt)
DK (1) DK1765289T3 (pt)
ES (1) ES2315880T3 (pt)
PL (1) PL1765289T3 (pt)
PT (1) PT1765289E (pt)
SI (1) SI1765289T1 (pt)
WO (1) WO2006002642A2 (pt)
ZA (1) ZA200701043B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2040745B1 (en) 2006-06-28 2012-12-05 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
CA2927045A1 (en) * 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
SI2167124T1 (sl) 2007-06-29 2012-12-31 Statens Serum Institut Uporaba monomikolil glicerola (mmg) kot adjuvansa
EP2711021B1 (en) 2008-05-02 2016-03-09 BliNK Therapeutics Limited Products and methods for stimulating an immune response
CN102325875B (zh) * 2009-01-08 2018-04-10 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
JP5854559B2 (ja) * 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
BR112012033751B1 (pt) * 2010-07-02 2021-06-01 Intervet International B.V. Composição de vacina e processo para produzir a composição de vacina
EP2729127B1 (en) 2011-07-04 2018-05-02 Statens Serum Institut Methods for producing liposomes
KR20140111272A (ko) * 2011-12-12 2014-09-18 교와 핫꼬 기린 가부시키가이샤 양이온성 지질의 조합을 함유하는 지질 나노 입자
JP6182457B2 (ja) * 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
JP2016175841A (ja) * 2013-08-02 2016-10-06 三郎 斎藤 リポソームと、細胞障害性ｔ細胞活性を誘導するワクチン組成物
UA130246C2 (uk) * 2013-09-19 2025-12-31 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
CN106535933B (zh) * 2014-08-04 2021-09-17 日东电工株式会社 包含核受体配体的免疫诱导促进用组合物以及疫苗药物组合物
EP3325015B1 (en) * 2015-07-20 2021-05-12 Zoetis Services LLC Liposomal adjuvant compositions
EP3774829A2 (en) 2018-04-13 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunigenic alpha-branched trehalose-diesters
KR20230002680A (ko) * 2020-04-15 2023-01-05 스태튼스 세룸 인스티튜트 병원성 감염의 예방 또는 조기 치료 용도의 리포솜 조성물
CN114657147B (zh) * 2022-01-27 2023-12-01 安徽智飞龙科马生物制药有限公司 一种生物材料的保护剂及其应用
CN115068602B (zh) * 2022-08-22 2022-11-01 北京华诺泰生物医药科技有限公司 一种表面改性氧化铝的复合疫苗佐剂、制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108934A (en) * 1983-11-30 1992-04-28 Kabushiki Kaisha Toshiba Quantitative immunoassay utilizing liposomes
JP2714972B2 (ja) * 1988-02-02 1998-02-16 千葉製粉株式会社 リン脂質集合体用修飾剤、リン脂質小胞体用凝集防止剤、リン脂質小胞体用融合防止剤およびリン脂質膜用表面固定化剤
JPH03249561A (ja) * 1990-02-28 1991-11-07 Toshiba Corp 免疫分析試薬
JPH0482824A (ja) * 1990-07-23 1992-03-16 Nippon Oil & Fats Co Ltd リポソーム及び水中油型エマルション
JPH0616688A (ja) * 1992-06-30 1994-01-25 Nippon Oil & Fats Co Ltd 脂肪酸糖エステル
JP3884488B2 (ja) * 1993-03-10 2007-02-21 千葉製粉株式会社 オリゴ糖脂質
JP3329554B2 (ja) * 1993-03-10 2002-09-30 千葉製粉株式会社 乾燥小胞体
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
JPH0925287A (ja) * 1995-07-13 1997-01-28 Eisai Co Ltd 合成脂質
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9808268D0 (en) * 1998-04-17 1998-06-17 Imp College Innovations Ltd Compound
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
JP2005525992A (ja) * 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用

Also Published As

Publication number Publication date
DK1765289T3 (da) 2008-12-15
BRPI0512757B1 (pt) 2021-04-06
JP2008505131A (ja) 2008-02-21
AU2005259685A1 (en) 2006-01-12
EP1765289A2 (en) 2007-03-28
SI1765289T1 (sl) 2009-02-28
KR20070051847A (ko) 2007-05-18
EP1765289B1 (en) 2008-09-03
CA2572985C (en) 2014-04-22
ES2315880T3 (es) 2009-04-01
DE602005009535D1 (de) 2008-10-16
ATE406874T1 (de) 2008-09-15
JP4987704B2 (ja) 2012-07-25
WO2006002642A3 (en) 2006-05-18
PL1765289T3 (pl) 2009-02-27
ZA200701043B (en) 2007-12-27
CA2572985A1 (en) 2006-01-12
WO2006002642A2 (en) 2006-01-12
PT1765289E (pt) 2008-12-05
CN1980638A (zh) 2007-06-13
CN1980638B (zh) 2011-10-12
AU2005259685B2 (en) 2010-04-08
BRPI0512757B8 (pt) 2021-05-25
KR101275837B1 (ko) 2013-06-18

Similar Documents

Publication Publication Date Title
BRPI0512757A (pt) método de estabilização de lipossomos catiÈnicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamìdia, malária ou tuberculose e sistema de distribuição
Lavelle et al. Mucosal vaccines—fortifying the frontiers
Schwendener Liposomes as vaccine delivery systems: a review of the recent advances
Alving et al. Adjuvants for human vaccines
Moser et al. Influenza virosomes as a vaccine adjuvant and carrier system
Tandrup Schmidt et al. Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators
Nordly et al. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators
Amorij et al. Needle-free influenza vaccination
Giddam et al. Liposome-based delivery system for vaccine candidates: constructing an effective formulation
Jabbal-Gill Nasal vaccine innovation
WO2005016239A3 (en) Molecules enhancing dermal delivery of influenza vaccines
Levast et al. Vaccine potentiation by combination adjuvants
Atmar et al. Adjuvants for pandemic influenza vaccines
Kersten et al. Antigen delivery systems
Dowling et al. Pediatric vaccine adjuvants: components of the modern vaccinologist’s toolbox
BR0014281A (pt) Vacina contra vìrus de gripe intranasal
TW200722101A (en) Novel composition
EP3556353A3 (en) Lipid nanoparticle vaccine adjuvants and antigen delivery systems
CA2448208A1 (en) Influenza vaccine composition
Even-Or et al. Adjuvanted influenza vaccines
MX2009000660A (es) Vacuna de influenza.
CN119968210A (zh) 用于预防或治疗结核病的rna
Akache et al. Adjuvants: engineering protective immune responses in human and veterinary vaccines
Glück et al. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems
Kim et al. Pharmaceutical and immunological evaluation of cholera toxin A1 subunit as an adjuvant of Hepatitis B vaccine microneedles

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.003382/2026-41 ORIGEM: 18A VARA FEDERAL CIVEL DA SJDF PROCESSO NO: 1140493-53.2025.4.01.3400 SUB JUDICE AUTOR: STATENS SERUM INSTITUT REU(S): INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL ? INPI